HomeHealthcarePharmaceuticals IV and Oral Iron Drugs Market

IV and Oral Iron Drugs Market Size, Share & Trends Analysis Report By Drug Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Ferric Gluconate, Others), By Route of Administration (IV, Oral), By Application (Chronic Kidney Diseases, Inflammatory Bowel Diseases, Oncology-induced Anemia, Iron Deficiency Anemia, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 02, 2026 | Author: Debashree Bora | Format:

IV and Oral Iron Drugs Market Size & Growth Analysis

The global iv and oral iron drugs market size was valued at USD 8.65 billion in 2025 and is projected to grow from USD 9.64 billion in 2026 to USD 22.91 billion by 2034, registering a CAGR of 11.43% . North America dominated the iv and oral iron drugs market with a share of 37.2% in 2025.

IV and oral iron drugs are iron-based medications used to prevent and treat iron deficiency and iron deficiency anemia by replenishing the body's iron levels. Oral iron drugs are taken as tablets, capsules, or liquids, while IV iron drugs are administered directly into the bloodstream to support faster iron replenishment when oral treatment is unsuitable or ineffective.

IV and Oral Iron Drugs Market Key Takeaways

Global Market Size & Growth

2025 Market Size
USD 8.65 Billion
2026 Market Size
USD 9.64 Billion
2034 Projected Market Size
USD 22.91 Billion
Forecast Period
2026–2034
Base Year
2025
Market CAGR (2026–2034)
11.43%

Regional Insights

Largest Regional Market (2025)
North America
North America Market Share (2025)
37.2%
Fastest-growing Region
Europe
Europe CAGR (2026–2034)
8.6%

Segment Insights

By Drug Type
Leading Segment
Ferric Carboxymaltose
Market Share in 2025 31.8%
By Route of Administration
Fastest-growing Segment
IV
CAGR (2026–2034) 8.5%
By Application
Leading Segment
Chronic Kidney Diseases
Market Share in 2025 28.6%
IV and Oral Iron Drugs Market Size , Share and Growth Forecast 2026-2034

Download a Free SampleTo learn more about this report.

IV and Oral Iron Drugs Market Dynamics

01

Iron Deficiency Anemia Diagnosis Drive Market

Routine blood tests and hemoglobin screening help identify iron deficiency anemia, supporting prescriptions for oral iron supplements and intravenous treatments based on patient needs. For example, diagnostic screening at hospitals and primary care clinics helps identify patients requiring iron therapy, creating consistent procurement opportunities for pharmaceutical suppliers.

02

Maternal Healthcare Programs Market Demand

Antenatal care programs include iron deficiency screening and supplementation to manage anemia during pregnancy and support maternal health. For example, hospitals and public health clinics provide oral iron tablets to pregnant women, supporting institutional purchases and supply opportunities for manufacturers of iron-based medicines.

03

Impact Analysis of Key Drivers in IV and Oral Iron Drugs Market

DriversMarket Impact

Iron Deficiency Anemia Diagnosis

Routine screening and diagnosis of iron deficiency anemia support prescriptions for oral and intravenous iron therapies, creating sales opportunities for pharmaceutical manufacturers.

Maternal Healthcare Programs

Pregnancy-related iron deficiency increases the need for iron supplementation, supporting procurement of oral iron medicines and injectable formulations by hospitals and clinics.

Chronic Kidney Disease Management

Patients with chronic kidney disease often require iron therapy to manage anemia associated with reduced kidney function, supporting the use of prescribed oral and intravenous iron drugs.

Gastrointestinal Disorders

Conditions such as inflammatory bowel disease can limit iron absorption or cause blood loss, encouraging the use of suitable iron therapies and supporting specialized treatment options.

Hospital Anemia Treatment Capacity

Hospitals require reliable supplies of injectable iron drugs for patients who cannot tolerate or adequately absorb oral supplements, supporting institutional procurement and pharmaceutical distribution.

01

Adverse Effects of Iron Therapy

Adverse effects such as nausea, constipation, abdominal discomfort, and infusion-related reactions can affect patient tolerance of iron treatments. These reactions may lead to missed doses or treatment discontinuation, reducing adherence and limiting the adoption of certain IV and oral iron formulations.

02

Risk of Iron Overload

The risk of iron overload arises when patients receive excessive iron doses or undergo repeated supplementation without proper assessment of iron levels. Potential complications increase the need for careful monitoring and restrict treatment use in patients who do not require additional iron, limiting broader adoption.

03

Impact Analysis of Key Restraints in IV and Oral Iron Drugs Market

RestraintsMarket Impact

Adverse Effects of Iron Therapy

Gastrointestinal discomfort from oral iron and infusion-related reactions associated with IV iron can affect treatment adherence, leading some patients to discontinue therapy or switch to alternative formulations.

Risk of Iron Overload

Excessive or unnecessary iron supplementation can cause iron accumulation and related complications, increasing the need for careful diagnosis and monitoring and limiting the use of iron therapies in certain patient groups.

Complex Administration and Monitoring

IV iron treatment requires trained healthcare professionals, suitable facilities, and patient monitoring, which can increase treatment complexity and restrict access in settings with limited healthcare infrastructure.

Diagnostic and Treatment Gaps

Delays in identifying iron deficiency and distinguishing it from other forms of anemia can postpone appropriate treatment, reducing timely use of IV and oral iron drugs.

Limited Treatment Adherence

Long treatment durations and the need for consistent dosing can make it difficult for patients to complete iron therapy, affecting treatment outcomes and reducing sustained demand for prescribed products.

01

Geriatric Iron Treatment Solutions and Gastrointestinal-Tolerant Formulations Offers Growth Opportunities

Older adults, hospitals, and long-term care providers benefit from iron treatments designed to address age-related nutritional needs and medication challenges. Specialized formulations, hospital supply agreements, and patient care programs create revenue opportunities for companies such as Viatris and Abbott.

Patients who experience digestive discomfort with conventional iron products benefit from formulations designed to improve tolerability and treatment adherence. Advanced formulation development, product licensing, and specialized oral iron therapies create revenue opportunities for companies such as Shield Therapeutics and Pharmacosmos, supporting iv and oral iron drugs market growth.

IV and Oral Iron Drugs Market Segmentation Analysis

By Drug Type 

Ferric carboxymaltose held the leading market share of 31.8%, as its high-dose administration and shorter treatment duration make it a preferred option for patients requiring rapid iron replenishment.
 
Iron sucrose recorded the highest CAGR of 7.1% during the forecast period, as its established use in patients with chronic kidney disease and its established safety profile support continued adoption.
IV and Oral Iron Drugs Market Size By Segments

Request Customizationto receive a tailored report.

By Route of Administration

IV recorded a CAGR of 8.5%, reflecting its use in treating severe iron deficiency and patients who require rapid iron replenishment.

Oral recorded a CAGR of 6.1%, supported by its convenience, affordability, and suitability for routine iron deficiency management.

By Application 

Chronic kidney diseases captured the leading market share of 28.6%, as impaired kidney function can reduce erythropoietin production and contribute to iron deficiency and anemia.
 
Inflammatory bowel diseases registered the highest CAGR of 8.3% during the forecast period, as intestinal inflammation and blood loss can impair iron absorption and increase the need for iron treatment.
IV and Oral Iron Drugs Market Share By Segments

Speak to an Analystto discuss market opportunities.

IV and Oral Iron Drugs Market Regional Outlook

North America IV and Oral Iron Drugs Market 

The North America iv and oral iron drugs market accounted for the largest share of 37.2% in 2025.

United States IV and Oral Iron Drugs Market 

The U.S. Preventive Services Task Force is reviewing evidence on iron-deficiency screening in pregnant women, with updated recommendations expected to influence clinical practice. Continued attention to maternal iron status and the management of iron-deficiency anaemia may shape demand for oral supplementation and, where clinically appropriate, intravenous iron therapy.

Canada IV and Oral Iron Drugs Market 

Canada's ageing population and growing focus on managing chronic diseases make iron-deficiency diagnosis and treatment important areas of healthcare. Future demand will be influenced by access to laboratory testing, treatment guidelines and the use of intravenous iron for patients who cannot tolerate or adequately respond to oral therapy.

North America IV and Oral Iron Drugs Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Camping IV and Oral Iron Drugs Market 

The Europe iv and oral iron drugs market is expected to grow at a CAGR of 8.6% during the forecast period.

U.K. IV and Oral Iron Drugs Market 

The UK's NHS continues to emphasise the diagnosis and treatment of iron-deficiency anaemia, including during pregnancy and in patients with chronic conditions. Clinical guidance on oral iron as an initial treatment and intravenous iron when oral therapy is unsuitable or ineffective helps define the country's treatment landscape.

Germany IV and Oral Iron Drugs Market 

Germany's established hospital network and specialist care for chronic kidney disease, gastrointestinal disorders and pregnancy support demand for both oral and intravenous iron treatments. The growing focus on individualised anaemia management is likely to influence treatment selection based on iron deficiency severity, patient tolerance and clinical setting.

Asia PacificIV and Oral Iron Drugs Market 

The Asia-Pacific iv and oral iron drugs market accounted for 23.1% of the global market in 2025.

Japan IV and Oral Iron Drugs Market 

Japan's ageing population makes the management of anaemia among older adults an important healthcare priority, particularly for patients with chronic kidney disease and other long-term conditions. The use of intravenous iron in specialist care and oral iron for suitable patients will remain relevant to treatment strategies.

China IV and Oral Iron Drugs Market 

China's large population and continued expansion of healthcare access create a substantial need for the diagnosis and treatment of iron-deficiency anaemia. Improvements in primary healthcare, maternal health services and hospital-based treatment are likely to influence the use of oral and intravenous iron therapies.

India IV and Oral Iron Drugs Market 

India's maternal and child health programmes make iron-deficiency anaemia a major public-health priority, with the Anemia Mukt Bharat programme continuing to promote screening, iron-folic acid supplementation and treatment. The programme's focus on pregnant women, children and adolescents supports the role of oral iron, while intravenous formulations are relevant for selected patients requiring faster or alternative treatment.

Competitive Landscape

The iv and oral iron drugs market is moderately fragmented, with pharmaceutical companies, generic drug manufacturers, and specialized healthcare providers competing across treatment formulations.Key players such as CSL, Daiichi Sankyo, Covis Pharma, Akebia Therapeutics, and Shield Therapeutics are estimated to collectively account for 20–25% of the global iv and oral iron drugs market share.
 
Established players compete through product efficacy, formulation quality, regulatory approvals, strong distribution networks, and established healthcare partnerships, while the iv and oral iron drugs market ecosystem also includes emerging players that focus on patient-friendly formulations, improved drug tolerability, cost-effective therapies, and innovative iron delivery solutions.
 

List of Key and Emerging Players in IV and Oral Iron Drugs Market

CSL Limited (Australia)
Daiichi Sankyo Company, Limited (Japan)
Covis Pharma GmbH (Switzerland)
Akebia Therapeutics, Inc. (U.S.)
Shield Therapeutics plc (United Kingdom)
Sanofi S.A. (France)
AbbVie Inc. (U.S.)
Pfizer Inc. (U.S.)
Rockwell Medical, Inc. (U.S.)
Fresenius Medical Care AG (Germany)
Zydus Lifesciences Limited (India)
Sun Pharmaceutical Industries Limited (India)
Dr. Reddy’s Laboratories Limited (India)
Cipla Limited (India)
Lupin Limited (India)
Emcure Pharmaceuticals Limited (India)
Aurobindo Pharma Limited (India)
Intas Pharmaceuticals Limited (India)
Glenmark Pharmaceuticals Limited (India)
Teva Pharmaceutical Industries Limited (Israel)
Viatris Inc. (U.S.)
Pharmacosmos A/S (Denmark)
Nippon Shinyaku Co., Ltd. (Japan)
Hikma Pharmaceuticals PLC (United Kingdom)

Recent Key Developments

September 2026
September 2026:The European Medicines Agency (EMA) initiated a safety review of injectable iron medicines following concerns about hypophosphatemia and associated bone complications, including osteomalacia. The review may lead to updated safety recommendations and changes to product authorizations for affected therapies.
June 2026
Viatris received FDA approval for its generic ferric carboxymaltose injection in three strengths. The product provides a substitutable alternative to Injectafer for eligible patients with iron deficiency anemia and certain other iron-deficiency conditions, strengthening generic competition in the IV iron segment.
April 2026
April 2026: China Medical System Holdings signed an exclusive commercialization and supply agreement with Pharmacosmos for Monofer (iron isomaltoside) and Cosmofer (iron dextran) in China. The agreement expands local access to established IV iron treatments and strengthens the company's presence in anemia management across multiple medical specialties.
March 2026
Australia's Therapeutic Goods Administration registered Carboferm, a generic ferric carboxymaltose product from Dr. Reddy's Laboratories. The medicine is indicated for iron deficiency when oral iron is ineffective, cannot be used, or rapid iron replacement is clinically required, expanding treatment options in the Australian market.

Report Scope

Segmentation

By Drug Type 5
  • Iron Dextran
  • Iron Sucrose
  • Ferric Carboxymaltose
  • Ferric Gluconate
  • Others
By Route of Administration 2
  • IV
  • Oral
By Application 5
  • Chronic Kidney Diseases
  • Inflammatory Bowel Diseases
  • Oncology-induced Anemia
  • Iron Deficiency Anemia
  • Others

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 8
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Singapore
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage CSL Limited (Australia) · Daiichi Sankyo Company, Limited (Japan) · Covis Pharma GmbH (Switzerland) · Akebia Therapeutics, Inc. (U.S.) · Shield Therapeutics plc (United Kingdom)
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Reportto Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The iv and oral iron drugs market size is valued at USD 9.64 Billion in 2026 and is projected to reach USD 22.91 Billion by 2034, at a CAGR of 11.43% during the forecast period 2026-2034.
North America dominated the market with a share of 37.2% in 2025.
The leading players in this market are CSL, Daiichi Sankyo, Covis Pharma, Akebia Therapeutics, Shield Therapeutics.
The iv and oral iron drugs market is projected to grow at a CAGR of 11.43% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
Trusted by Industry Leaders
LG ElectronicsAMCAD EngineeringKOBE STEEL LTD.Hindustan National Glass & Industries LimitedVoith GroupInternational PaperHansol PaperWhirlpool CorporationSonySamsung ElectronicsQualcommGoogleFiservVeto-PharmaNippon Becton DickinsonMerckArgon Medical DevicesAbbottAjinomotoDenonDoosanMeiji Seika Kaisha LtdLG ChemicalsLCY chemical groupBayerAirraneBASFToyota IndustriesNissan MotorsNeenahMitsubishiHyundai Motor CompanyHondaCRP Industries IncpewagLGEPanasonicLubrizol CorporationLeonardoJohnson & JohnsonHB FullerMITSUBISHI CHEMICALHyundai MobisAmazon
Request SampleOrder Report Now